Araştırma Makalesi

The relationship between ghrelin and ghrelin leu72met polymorphism in coronary artery disease

Cilt: 48 Sayı: 2 2 Temmuz 2023
PDF İndir
TR EN

The relationship between ghrelin and ghrelin leu72met polymorphism in coronary artery disease

Öz

Purpose: Ghrelin represents a hormone, which is defined as an endogenous ligand bound to the growth hormone-releasing hormone receptor (GHS-R1a). However, the mechanisms that underlie ghrelin’s impacts on cardiovascular diseases have not been completely detected. For this reason, we aimed to research the relationship between serum ghrelin and ghrelin gene polymorphism in coronary artery disease (CAD). Materials and Methods: The study group consisted of 88 patients diagnosed with a minimum of one coronary artery stenosis over 70%, and the control group comprised 81 individuals without coronary artery lesions. An autoanalyzer was used to analyze fasting blood glucose (FBG) and lipid parameter levels. Ghrelin levels were examined with an enzyme-linked immunosorbent assay (ELISA) kit. Results: Ghrelin levels were found to be 2.2 ng/ml in the control group and 2.1 ng/ml in the CAD group. No statistical relation in ghrelin Leu72Met genotypes were detected between the control and patient groups. Conclusion: Serum ghrelin levels were higher in the control group than in the CAD group. Whether ghrelin levels and Leu72Met polymorphism have protective effects in CAD must be revealed in an extensive study group with other polymorphisms and ghrelin expression in the ghrelin gene.

Anahtar Kelimeler

Ghrelin, Coronary artery disease, Leu72Met, polymorphism

Destekleyen Kurum

Mersin University Scientific Research Projects Department

Proje Numarası

2017-2-AP2-2626

Kaynakça

  1. REFERENCES
  2. Gensini GF, Comeglio M, Colella A. Classical risk factors and emerging elements in the risk profile for coronary artery disease. Eur Heart J. 1998;19:53–61.
  3. Marenberg ME, Risch N, Berkman LF, Floderus B, de Faire U. Genetic susceptibility to death from coronary heart disease in a study of twins. N Engl J Med. 1994;330:1041–46.
  4. Ferri N, Paoletti R, Corsini A. Lipid-modified proteins as biomarkers for cardiovascular disease: a review. Biomarkers. 2005;10:219-37.
  5. Akamizu T, Kangawa K. The physiological significance and potential clinical applications of ghrelin. Eur J Intern Med. 2012;23:197-202.
  6. Kojima M, Hosoda H, Date Y, Nakazato M, Matsuo H, Kanagawa K. Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature. 1999;402:656–60.
  7. Kojima M, Kangawa K. Grelin: structure and function. Physiol Rev. 2005;85:495-522.
  8. Aydin S, Ozkan Y, Caylak E, Aydin S. Grelin and its biochemical functions. Turkiye Klinikleri J Med Sci. 2006;26:272-83.
  9. Kierson JA, Dimatteo DM, Locke RG, Mackley AB, Spear ML. Grelin and cholecystokinin in term and preterm human breast milk. Acta Paediatr. 2006;95:991-5.
  10. Aydin S, Ozercan İH, Dagli F, Aydin S, Kumru S, Kilic N et al. Grelin is present in human teeth. J Biochem Mol Biol. 2007;40:368-72.

Kaynak Göster

APA
Yıldırım Yaroğlu, H., Özkan, B., Balcı, S., Ünal, Z. N., Erden Ertürk, S., Dilek çiçek, D., & Tamer, L. (2023). The relationship between ghrelin and ghrelin leu72met polymorphism in coronary artery disease. Cukurova Medical Journal, 48(2), 637-643. https://doi.org/10.17826/cumj.1243029
AMA
1.Yıldırım Yaroğlu H, Özkan B, Balcı S, vd. The relationship between ghrelin and ghrelin leu72met polymorphism in coronary artery disease. Cukurova Med J. 2023;48(2):637-643. doi:10.17826/cumj.1243029
Chicago
Yıldırım Yaroğlu, Hatice, Buğra Özkan, Senay Balcı, vd. 2023. “The relationship between ghrelin and ghrelin leu72met polymorphism in coronary artery disease”. Cukurova Medical Journal 48 (2): 637-43. https://doi.org/10.17826/cumj.1243029.
EndNote
Yıldırım Yaroğlu H, Özkan B, Balcı S, Ünal ZN, Erden Ertürk S, Dilek çiçek D, Tamer L (01 Temmuz 2023) The relationship between ghrelin and ghrelin leu72met polymorphism in coronary artery disease. Cukurova Medical Journal 48 2 637–643.
IEEE
[1]H. Yıldırım Yaroğlu vd., “The relationship between ghrelin and ghrelin leu72met polymorphism in coronary artery disease”, Cukurova Med J, c. 48, sy 2, ss. 637–643, Tem. 2023, doi: 10.17826/cumj.1243029.
ISNAD
Yıldırım Yaroğlu, Hatice - Özkan, Buğra - Balcı, Senay - Ünal, Zeynep Nil - Erden Ertürk, Sema - Dilek çiçek, Dilek çiçek - Tamer, Lülüfer. “The relationship between ghrelin and ghrelin leu72met polymorphism in coronary artery disease”. Cukurova Medical Journal 48/2 (01 Temmuz 2023): 637-643. https://doi.org/10.17826/cumj.1243029.
JAMA
1.Yıldırım Yaroğlu H, Özkan B, Balcı S, Ünal ZN, Erden Ertürk S, Dilek çiçek D, Tamer L. The relationship between ghrelin and ghrelin leu72met polymorphism in coronary artery disease. Cukurova Med J. 2023;48:637–643.
MLA
Yıldırım Yaroğlu, Hatice, vd. “The relationship between ghrelin and ghrelin leu72met polymorphism in coronary artery disease”. Cukurova Medical Journal, c. 48, sy 2, Temmuz 2023, ss. 637-43, doi:10.17826/cumj.1243029.
Vancouver
1.Hatice Yıldırım Yaroğlu, Buğra Özkan, Senay Balcı, Zeynep Nil Ünal, Sema Erden Ertürk, Dilek çiçek Dilek çiçek, Lülüfer Tamer. The relationship between ghrelin and ghrelin leu72met polymorphism in coronary artery disease. Cukurova Med J. 01 Temmuz 2023;48(2):637-43. doi:10.17826/cumj.1243029